A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.

Sci Rep · 2022 · PMC8828770 · PMID 35140308

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

5 E, we observed a clear trend that patients with higher C-scores were more correctly predicted from their Oncotype DX scores by the CPM.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.